This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims: Please amend the claims as follows:

We claim:

Claim 1. (Withdrawn) A method of removing antibodies specific for B7-H1 from a body fluid of a subject, the method comprising:
(a) withdrawing a body fluid from a subject, wherein the body fluid comprises one or more antibodies that bind to B7-Hl;
(b) removing from the body fluid a substantial portion of the one or more antibodies; and
(c) returning the body fluid to the subject.

Claim 2. (Withdrawn) The method of claim 1, wherein the body fluid is blood plasma.

Claim 3. (Withdrawn) The method of claim 1, wherein the subject is suspected of having a disease or pathological condition, or is likely to develop a disease or pathological condition, with symptoms that are caused directly, or indirectly, by activated cells.

Claim 4. (Withdrawn) The method of claim 3, wherein the disease is an autoimmune disease.

Claim 5. (Withdrawn) The method of claim 4, wherein the autoimmune disease is rheumatoid arthritis.

Claim 6. (Withdrawn) The method of claim 4, wherein the autoimmune disease is systemic lupus erythematosus.

Claim 7. (Withdrawn) The method of claim 4, wherein the autoimmune disease is autoimmune hearing loss.

Claim 8. (Withdrawn) The method of claim 1, wherein the removal comprises contacting the body fluid with a B7-Hl reagent.

Claim 9. (Withdrawn) The method of claim 8, wherein B7-H1 reagent is bound to a solid support.

Claim 10. (Withdrawn) The method of claim 2, wherein prior to the removal step, the blood plasma is separated from blood cells.

Claim 11. (Withdrawn) A method of treatment comprising:

(a) identifying a subject as having an elevated level in a body fuid of one or more B7H1-specifc antibodies; and
(b) administering to the subject one or more compounds that inhibit the binding of B7-H1 to one or more B7-H1-specifc antibodies.

Claim 12. (Withdrawn) The method of claim 11, wherein the body fuid is blood.

Claim 13. (Withdrawn) The method of claim 11, wherein the subject is suspected of having a disease or pathological condition, or is likely to develop a disease or pathological condition, with symptoms that are caused directly, or indirectly, by activated T cells.

Claim 14. (Withdrawn) The method of claim 13, wherein the disease is an autoimmune disease.

Claim 15. (Withdrawn) The method of claim 14, wherein the autoimmune disease is rheumatoid arthritis.

Claim 16. (Withdrawn) The method of claim 14, wherein the autoimmune disease is systemic lupus erythematosus.

Claim 17. (Withdrawn) The method of claim 14, wherein the autoimmune disease is autoimmune hearing loss.

Claim 18. (Withdrawn) The method of claim 11, wherein the compound comprises B7-H1 or a fragment of B7-Hl.

Claim 19. (Previously Presented) A method of diagnosis, comprising:

(a) identifying a subject that is suspected of having an autoimmune disease;

(b) obtaining a sample of body fluid from the subject; and

(c) testing for the presence in the sample of one or more antibodies that bind to human wild-type B7-H1,

wherein an elevated level in the sample of one or more antibodies that bind to human wild-type B7-H1 is an indication that the subject has an autoimmune disease.

Claim 20. (Cancelled)

Claim 21. (Previously Presented) The method of claim 19, wherein the autoimmune disease is rheumatoid arthritis.

Claim 22. (Previously Presented) The method of claim 19, wherein the autoimmune disease is systemic lupus erythematosus.

Claim 23. (Previously Presented) The method of claim 19, wherein the autoimmune disease is autoimmune hearing loss.

Claim 24. (Original) The method of claim 19, wherein the body fluid is blood.

Claim 25. (Currently Amended) A method of monitoring the progress of a disease, ~~the method~~ comprising:

(a) identifying a subject that is suspected of having an autoimmune disease;

(b) obtaining a sample of body fluid from the subject; and

(c) testing for the presence in the sample of one or more antibodies that bind to human wild-type B7-H1,

wherein an elevated level in the sample of one or more antibodies that bind to human wild-type B7-H1 is an indication that the subject has an autoimmune disease and directly correlates with the existence of the ~~an~~ active stage of the autoimmune disease.

Claim 26. (Original) The method of claim 25, further comprising repeating steps (b) and (c) one or more times.

Claim 27. (Cancelled)

Claim 28. (Previously Presented) The method of claim 25, wherein the autoimmune disease is rheumatoid arthritis.

Claim 29. (Previously Presented) The method of claim 25, wherein the autoimmune disease is systemic lupus erythematosus.

Claim 30. (Previously Presented) The method of claim 25, wherein the autoimmune disease is autoimmune hearing loss.

Claim 31. (Original) The method of claim 25, wherein the body fluid is blood.

Claim 32. (Withdrawn) A method of identifying a compound that inhibits binding of B7-H1 to an antibody that binds to B7-H1, the method comprising contacting B7-H1 with the antibody in the presence of the compound and testing for inhibition by the compound of binding of B7-Hl to the antibody.

Claim 33. (Withdrawn) A method of designing a compound that inhibits the binding of B7-H1 to an antibody that binds to B7-H1, the method comprising analyzing the three dimensional
structure of B7-H1, or a fragment of B7-H1, and designing a compound with a three-dimensional structure that corresponds to an external portion of B7-Hl, wherein the compound binds to an antibody that binds to B7-H1.

Claim 34. (Withdrawn) A method of inhibiting expression of B7-H1 in a T cell, the method comprising introducing into the T cell: (a) an antisense oligonucleotide that hybridizes to a B7H1 transcript, wherein the antisense oligonucletide inhibits expression of B7-H1 in the cell; or (2) a B7-H1 interference RNA (RNAi).

Claim 35. (Withdrawn) The method of claim 34, wherein the introducing step comprises administration of the antisense oligonucleotide or the RNAi to the cell and uptake of the antisense oligonucleotide or the RNAi by the cell.

Claim 36. (Withdrawn) The method of claim 34, wherein the introducing step comprises

administering to the cell a nucleic acid comprising a transcriptional regulatory element (TRE) operably linked to a nucleotide sequence complementary to the antisense oligonucleotide,

wherein transcription of the nucleotide sequence inside the cell produces the antisense oligonucleotide.

Claim 37. (Withdrawn) The method of claim 34, wherein the introducing step comprises administering to the T cell a nucleic acid: (a) from which sense and anti-sense strands of the RNAi can be transcribed under the direction of separate TREs; or (b) from which both sense and anti-sense strands of the RNAi can be transcribed under the.direction of a single TRE.

Claim 38. (Withdrawn) The method of claim 34, wherein the T cell is in a mammal.

Claim 39. (Withdrawn) The method of claim 38, wherein the mammal is a human.